Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Thromboelastography (TEG) is a viscoelastic hemostatic assay that measures the visco-elastic properties of blood clot formation. It is mainly used in surgery and anesthesiology. This test is capable of measuring coagulation factor function. Some of the other tests for blood coagulation includes prothrombin time and partial thromboplastin time (aPTT). However, thromboelastography provides information regarding all components of hemostasis such as coagulation and platelet function. Also, TEG offers a particular advantage in diagnosing fibrinolysis. TEG machines are used for carrying out this test.
The global thromboelastography market size is estimated to be valued at US$ 531.8 million in 2020 and is expected to exhibit a CAGR of 7.2% over the forecast period (2020-2027).
Figure 1. Global Thromboelastography Market Value (US$ Mn), by Region, 2020
Rising patient population suffering from life>
Figure 2. Global Thromboelastography Market Share (%), by Type, 2020
Increasing adoption of strategies such as mergers, agreements, and collaborations by key players is expected to drive the market growth over the forecast period
Market players are focused on adoption of inorganic growth strategies such as collaborations and agreements to strengthen their position in the thromboelastography market. For instance, in April 2020, Haemonetics Corporation announced the acquisition of enicor GmbH, a manufacturer of whole blood coagulation testing system – ClotPro. This system is expected to strengthen its product capabilities such as TEG 5000 Hemostasis Analyzer and the TEG 6s Hemostasis Analyzer, and offer better products in the market. The ClotPro system reduces the need for annual pipetting and also eliminates reagent handling issues.
Thromboelastography Market Report Coverage
||Market Size in 2019:
||US$ 531.8 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 863.9 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Type: Standard, RapidTEG, Functional Fibrinogen, Platelet Mapping, Heparinase, Consumables & Disposables.
- By Application: Cardio-pulmonary Bypass Surgery, Liver Transplantation, Trauma, Obstetrics, Neonatology and Pediatrics, Others.
- By End User: Hospitals & Clinics, Blood Banks, Academic Institutes, Others.
Haemonetics Corporation, Instrumentation Laboratory, Framar Hemologix srl, Medirox AB, Diagnostica Stago, and Life Diagnostica
- Increasing life>
- Increasing number of surgical procedures
|Restraints & Challenges:
- Limitations of thromboelastography
Thromboelastography Market Restraints
Thromboelastography is a promising and highly sensitive test for identifying underlying coagulopathy following traumatic brain injury. However, the confirmation with conventional coagulation tests (CCTs) is recommended, which is a time consuming and lengthy procedure.
Moreover, for performing a thromboelastography analysis in a laboratory setting, the transportation of blood sample for more than five minutes is required, which is the upper limit for running native blood samples and hence, storage of the blood sample in citrate or heparin becomes necessary. The use of citrate storage has been reported to influence the results of the thromboelastography analysis. Thus, such drawbacks of thromboelastography is expected to hinder the market growth.
Global Thromboelastography Market – Impact of Coronavirus (Covid-19) Pandemic
COVID-19 infected patients may face a high risk of developing kidney failure, stroke, and other complications associated with blood clot formation. According to the researchers from the University of Colorado Anschutz Medical Campus, Aurora, early thromboelastography (TEG) assay may be useful to identify COVID-19 patients who may need more anticoagulation therapy to prevent complications due to clot formation.
Moreover, it is recommended that all patients with COVID-19 should undergo coagulation studies at admission, as there is significant increase in D-dimer and prothrombin with a decrease in fibrinogen observed in COVID-19 patients who are at high risk (non-survivors at days 10-14). This is expected to accelerate the use of coagulopathy screening test including thromboelastography (TEG) assay and other conventional coagulation tests in the clinical setting.
Increasing prevalence of COVID-19, especially among the patients with existing severe health conditions/disorders, is expected to create a conducive environment for global thromboelastography market growth. For instance, according to the study by Hypertension Research (2020), acute cardiac injury is the most frequently reported cardiovascular abnormality in COVID-19 patients and it occurs in around 8–12% of all COVID-19 patients.
Major players operating in the global thromboelastography market include Haemonetics Corporation, Instrumentation Laboratory, Framar Hemologix srl, Medirox AB, Diagnostica Stago, and Life Diagnostica.